Lupin shares in focus after Q1 profit jumps 52% YoY to Rs 1,221 crore

Lupin shares will be in focus on Wednesday after the pharmaceutical company reported a 52% year-on-year rise in consolidated net profit to Rs 1,221 crore for the June quarter, driven by strong growth in the US and Indian markets. In the same quarter last year, the company had posted a profit of Rs 805 crore.

Sales rose to Rs 6,164 crore in the first quarter as against Rs 5,514 crore in the year-ago period.

“We continue to build strong business momentum, anchored by a robust product portfolio, improved efficiencies, and effective use of assets and investments,” said Nilesh Gupta, Managing Director, Lupin. “As we begin the year, our sharpened focus on compliance, innovation, and technology positions us to further unlock sustainable growth,” he added.


Also Read: These 10 stocks delivered consistent dividend yields over the last 3 years

The company said its sales in the US stood at Rs 2,404 crore in the June quarter, registering a growth of 24% as compared to Rs 1,934 crore in the year-ago period.

Lupin shares price target

According to Trendlyne, the average target price for Lupin stands at Rs 2,230, implying a 20% potential upside from current levels. The stock holds a ‘Buy’ rating from 37 analysts.

On Tuesday, Lupin shares closed 1% lower at Rs 1,863.3 on the BSE, even as the benchmark Sensex declined 0.38%. Year-to-date, the stock is down 21%, but it has gained 75% over the last two years. The company’s market capitalisation currently stands at Rs 85,108 crore.

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specialises in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

Also Read: PNB Housing Finance, RBL Bank among 10 small-cap stocks where FIIs increased stake in Q1

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)